(Q47400100)

15 January 2018

title

Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome (English)

1 reference

15 January 2018

author

Christine Mannhalter

13

1 reference

15 January 2018

author name string

Simonitsch-Klupp I

1

1 reference

15 January 2018

Hauser I

2

1 reference

15 January 2018

Ott G

3

1 reference

15 January 2018

Drach J

4

1 reference

15 January 2018

Ackermann J

5

1 reference

15 January 2018

Kaufmann J

6

1 reference

15 January 2018

Weltermann A

7

1 reference

15 January 2018

Greinix HT

8

1 reference

15 January 2018

Skrabs C

9

1 reference

15 January 2018

Dittrich C

10

1 reference

15 January 2018

Lutz D

11

1 reference

15 January 2018

Pötter R

12

1 reference

15 January 2018

Lechner K

14

1 reference

15 January 2018

Chott A

15

1 reference

15 January 2018

Jaeger U

16

1 reference

15 January 2018

publication date

1 January 2004

1 reference

15 January 2018

published in

Leukemia

1 reference

15 January 2018

volume

18

1 reference

15 January 2018

issue

1

1 reference

15 January 2018

page(s)

146-155

1 reference

15 January 2018

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403206

exact match

0 references

cites work

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Drug resistance factors in acute myeloid leukemia: a comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Expression of the ALK tyrosine kinase gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

7 January 2021

ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

7 January 2021

Chemotherapy of non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

7 January 2021

Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403206

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403206

1 reference

15 January 2018

PubMed ID

14603341

1 reference

15 January 2018